Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. reports recurring updates about its pharmaceutical royalty business, which owns rights to royalties from licensed pharmaceutical products and no longer conducts research and development or commercial operations. The company’s news is centered on license revenue, primarily under the Mayne License Agreement, changes in sales of licensed products, operating expense levels after its transition to a royalty-based model, and results from continuing operations.
TherapeuticsMD also provides corporate strategy updates, including disclosures about its ongoing evaluation of strategic alternatives. Its historical context includes a December 2022 shift from a women’s healthcare commercialization business to a company focused on collecting royalties from licensees.
TherapeuticsMD (NASDAQ: TXMD) has presented Phase 3 data for ANNOVERA, its FDA-approved contraceptive, showcasing favorable menstrual bleeding profiles at the 2021 ACOG Annual Meeting. The analysis included data from 2,070 women over 453,622 patient-days, indicating 94.8% to 97.6% reported no unscheduled bleeding across 13 cycles. Discontinuation due to bleeding-related issues was under 2%. ANNOVERA offers a long-lasting, patient-controlled contraceptive option but comes with significant risk warnings, particularly for women over 35 who smoke.
TherapeuticsMD, Inc. (NASDAQ: TXMD), a leader in women’s healthcare, will report Q1 2021 financial results on May 6, 2021, before U.S. market opening. Following this, an executive management conference call and webcast is scheduled for 8:30 a.m. ET to discuss the results and provide a business update. Investors can access the call via telephone or through a live audio webcast on the company's website. Replays will be available for 30 days. TherapeuticsMD specializes in products for family planning, reproductive health, and menopause management.
TherapeuticsMD, Inc. (NASDAQ: TXMD) and Theramex announced the approval of BIJUVE® in the UK and BIJUVA® in Belgium by respective regulatory agencies. This approval follows a decentralized procedure completed in February for several EU countries. Both medications represent the first oral combined hormone replacement therapy utilizing bio-identical hormones for post-menopausal women. Theramex will pay milestone and royalty fees to TherapeuticsMD based on sales and approvals in Europe.
TherapeuticsMD reported record net product revenue for Q4 2020 and the full year, driven by strong sales of its products. Total revenue for Q4 was $22.6 million, a rise from $15.9 million in Q4 2019. The company recorded a net loss of $42.1 million for Q4, an improvement from $49.4 million a year earlier. Operating expenses increased to $51.6 million in Q4, mainly attributed to ongoing product launches and brand management. The cash on hand at year-end was $80.5 million. The company is adjusting its revenue covenants and plans further debt repayments in 2021.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will participate in two upcoming investor conferences, showcasing its commitment to women’s healthcare. The first event is the Cowen Virtual Healthcare Conference on March 3, 2021, at 3:20 p.m. Eastern time. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, with a presentation available at 11:00 a.m. Eastern time. Live webcasts can be accessed through the company’s website. TherapeuticsMD focuses on innovative products for women, addressing key health issues throughout their lives.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced its fourth quarter 2020 financial results reporting on Tuesday, March 2, 2021, before U.S. market opening. The company will hold a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can access the call via telephone at 866-665-9531 for U.S. callers or 724-987-6977 for international calls, using access code 6184646. The event will also be available via a live audio webcast on their website.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed its underwritten public offering of 59,459,460 shares of common stock, generating approximately $97.1 million in net proceeds. The offering was fully sold by TherapeuticsMD, which has also granted the underwriter a 30-day option to acquire up to 8.9 million additional shares. Cantor Fitzgerald & Co. served as the sole bookrunning manager. This follows a previously effective shelf registration statement filed with the SEC.
TherapeuticsMD, Inc. (NASDAQ:TXMD) announced an underwritten public offering of approximately 59.5 million shares at a gross proceeds of $110 million, closing expected around February 16, 2021. Cantor Fitzgerald & Co. is the bookrunning manager, with a 30-day option for the underwriter to purchase an additional 8.9 million shares. Proceeds will be used for commercialization of FDA-approved products like IMVEXXY®, BIJUVA®, and ANNOVERA®, along with debt discharge and working capital.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, allowing the underwriter a 30-day option to purchase an additional 15% of offered shares. All shares will be sold by the company, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. Proceeds from the offering are intended for commercialization of three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®, as well as to reduce existing debt and general corporate purposes.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will participate in two upcoming investor conferences: the H.C. Wainwright BioConnect Conference from January 11-14, 2021, and the J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 8:20 a.m. Eastern time. Presentations will be available online during the events. TherapeuticsMD specializes in women’s healthcare, focusing on products for family planning, reproductive health, and menopause management. For more details, visit therapeuticsmd.com.